

# Insulin Resistance and Hypertension in Non-obese Africans in Tanzania

Yasin M. Mgonda, Kaushik L. Ramaiya, Andrew B.M. Swai,  
Donald G. McLarty†, K. George M.M. Alberti

**Abstract**—Insulin sensitivity was assessed using a glucose–insulin infusion test in 15 newly diagnosed non-obese hypertensive black Tanzanians with normal glucose tolerance and in 15 normotensive control subjects matched for age, sex, and body mass index. The steady-state blood glucose and metabolic clearance rate of glucose (MCR) were used as measures of insulin sensitivity. The mean MCR (glucose) was significantly reduced ( $7.12 \pm 0.57$  versus  $9.50 \pm 0.69$   $\mu\text{mol/kg}$  per minute;  $P < .05$ ) and mean steady-state blood glucose was significantly elevated ( $5.0 \pm 0.3$  versus  $3.7 \pm 0.3$  mmol/L;  $P < .01$ ) in subjects with hypertension compared with the normotensive group. For all subjects there was a significant inverse correlation between MCR (glucose) and systolic ( $P = .003$ ) and diastolic ( $P = .005$ ) blood pressure; and a positive correlation was found between fasting serum insulin levels and systolic ( $P = .005$ ) and diastolic ( $P = .004$ ) blood pressure. These observations were independent of body mass index and serum lipid levels. These data indicate a strong association between insulin mediated glucose uptake and blood pressure in this population of normal weight untreated urban Africans. (*Hypertension*. 1998;31[part 1]:114-118.)

**Key Words:** insulin resistance ■ Africans ■ blood pressure

A significant association has been demonstrated and confirmed between insulin resistance and essential hypertension, independent of glucose intolerance, and obesity.<sup>1-11</sup> This finding forms part of the hypothesis that insulin resistance is central to the cluster of abnormalities (abnormal glucose tolerance, obesity, hypertension, and dyslipidemia) known as Syndrome X or the metabolic syndrome.<sup>12-14</sup>

There is uncertainty as to whether the association between insulin resistance and hypertension applies to all populations. Epidemiological studies have cast doubt on the strength of this association in both Mauritians<sup>15</sup> and Californians.<sup>16</sup> Similarly, no correlation was reported between fasting serum insulin concentration and blood pressure measurements in normotensive black South Africans,<sup>17</sup> although another recent report suggests that insulin resistance is an independent feature of essential hypertension in that group.<sup>18</sup> No attention has been paid to this problem in other less-Westernized African settings. The main objective of this study therefore was to establish whether insulin resistance (insulin mediated glucose disposal) was associated with essential hypertension independent of obesity and glucose intolerance in African subjects in Dar es Salaam, Tanzania.

## Methods

A total of 280 employees of Kilimanjaro Hotel, Ltd, the biggest tourist hotel in the city of Dar es Salaam, were screened for hypertension. Of those screened, 30 African subjects (15 patients and 15 control

subjects) were enrolled for the study after obtaining informed consent from each subject. All subjects were from similar socioeconomic and occupational backgrounds, and all were physically active. They had a semi-Westernized diet, and the two groups were matched for age, sex, and body mass index. Hypertension was defined as blood pressure equal to or more than 160/95 mm Hg recorded on at least three occasions; body mass index was less than 30 kg/m<sup>2</sup>, and they had normal oral glucose tolerance based on 1985 WHO criteria.<sup>19</sup> Exclusion criteria included subjects with clinical and biochemical evidence of cardiac, hepatic, renal, and endocrine disease, known as hypertension, history of excessive alcohol consumption, excessive smoking, and, for female subjects, the use of oral contraceptives. No subject was taking or had ever taken antihypertensive medication.

## Physical Measures

### Blood Pressure

Blood pressure was measured on three different occasions using a mercury sphygmomanometer. After measuring blood pressure on day 1, a second measurement was obtained about a week later, and a third measurement 1 to 3 days later. On each occasion at least 2 readings were taken and the mean value recorded. An appropriate adult cuff was applied 2 to 3 cm above the antecubital fossa of the right arm. Blood pressure was measured to the nearest 2 mm Hg, reading the calibration below the meniscus with the subject in the sitting position. Systolic and diastolic blood pressures were read at the 1st and 5th Korotkoff phases, respectively. The mean of the 3 blood pressure values obtained from the 3 visits was taken as the subject's true blood pressure. Hypertension was defined as systolic and diastolic blood pressure equal to or more than 160 mm Hg and/or 90 mm Hg, respectively.

Received January 29, 1997; first decision February 21, 1997; revision accepted July 24, 1997.

From the Muhimbili University College of Health Sciences (Y.M.M., K.L.R., A.B.M.S., D.G.M), University of Dar es Salaam, Tanzania; Shree Hindu Mandal Hospital (K.L.R.), Dar es Salaam, Tanzania; and Department of Medicine (K.G.M.M.A.), University of Newcastle on Tyne, UK.

Correspondence to Professor K.G.M.M. Alberti, Department of Medicine, The Medical School, Framlington Place, Newcastle on Tyne, NE2 4HH, UK.

E-mail george.alberti@ncl.ac.uk

†Deceased.

© 1998 American Heart Association, Inc.

### Selected Abbreviations and Acronyms

BMI = body mass index
GIR = glucose infusion rate
HOMA = homeostatic model assessment
I/G = insulin to glucose ratio
MCR = metabolic clearance rate of glucose
SSBG = steady-state blood glucose
SSPI = steady-state plasma insulin
SPSS = Statistical Package for Social Sciences
WHO = World Health Organization

### Anthropometry

Weight was measured using a Seca bathroom weighing scale without shoes and in light clothing. Weight was recorded to the nearest 0.5 kg. Height was measured without shoes and/or cap and was recorded to the nearest centimeter. BMI is expressed as weight (kilograms) per height (meters) squared.

Waist circumference was taken as the maximum abdominal girth and recorded to the nearest centimeter. Hip circumference was taken as the maximum circumference at the level of the greater trochanter and also recorded to the nearest centimeter. The waist/hip ratio was calculated by dividing the waist circumference by the hip circumference in centimeters. Body fat percentage was determined using bioelectric impedance measurement.<sup>20</sup>

### Biochemical Measures

#### Oral Glucose Tolerance Test

All subjects underwent a 75-g oral glucose tolerance test. After an overnight fast (10 to 14 hours) subjects reported to the study center by 8:00 AM. After a short rest, fasting blood samples were collected from the antecubital vein and immediately placed in fluoride oxalate and analyzed immediately by the glucose oxidase method using a Yellow Springs analyzer (Yellow Springs). Other aliquots were kept in an ice-cold container and, within 4 hours of collection, were centrifuged and kept frozen at  $-40^{\circ}\text{C}$  until the serum samples were transported to Newcastle on Tyne, UK, for determination of serum cholesterol, triglyceride, and insulin levels. Glucose, 75 g, dissolved in 300 mL of water was consumed in about 5 minutes. Blood samples for determination of blood glucose and serum insulin were collected at 15, 30, 60, and 120 minutes. For quality control of glucose measurements, aliquots were stored and frozen for analysis by a hexokinase fluorimetric method using a Cobas Bio centrifugal analyzer (Roche Products, Ltd.) in Newcastle on Tyne.

#### Insulin Sensitivity Test

Insulin sensitivity was assessed in both patients and control subjects. The modified Harano technique (glucose-insulin infusion technique) was used.<sup>21</sup> Subjects reported at the study center on the morning of the procedure at around 8:00 AM after an overnight fast of 10 to 14 hours. A polytetrafluoroethylene cannula was inserted retrogradely in a dorsal hand vein for sampling venous blood that was arterialized by warming the hand at an approximate temperature of  $55^{\circ}\text{C}$  using a thermoregulated Plexiglas box. A butterfly needle was inserted in a contralateral hand vein and used for administration of 20% glucose (200 g/L) (1.1 mmol/L) and insulin. Glucose was infused at 6 mg (33 pmol)/kg per minute together with human soluble insulin (Actrapid, Novo Nordisk) at 50 mU/kg per hour (300 pmol/kg per hour) diluted in 30 mL of Hemaccel (Hoechst) for 180 minutes. Basal blood samples were collected at 30, 60, 90, 120, and 150 minutes and then every 5 minutes from 150 to 180 minutes. Blood glucose was analyzed as mentioned above. Blood samples for serum insulin and serum C-peptide analysis were kept on ice and centrifuged within 4 hours of collection and frozen at  $-40^{\circ}\text{C}$ .

The SSBG was determined from the mean 7 blood glucose values (time: 150, 155, 160, 165, 170, 175, 180 minutes). The SSPI was determined similarly. The metabolic clearance rate during 150 to 180

**TABLE 1. Clinical Characteristics of Hypertensive and Normotensive Subjects**

Variable	Hypertensive (n=15)	Normotensive (n=15)
Sex, M/F	11/4	11/4
Age, y	38.5 (1.7)	38.6 (1.8)
Body mass index, kg/m <sup>2</sup>	24.6 (0.9)	24.4 (0.9)
Waist-hip ratio	0.89 (0.02)	0.89 (0.01)
Body fat, %	25.5 (2.8)	18.1 (2.7)
Systolic BP, mm Hg	178 (6) <sup>§</sup>	131 (3)
Diastolic BP, mm Hg	111 (2) <sup>§</sup>	83 (5)

<sup>§</sup> $P < .001$ .

minutes was calculated by dividing GIR by SSBG concentration. Basal insulin sensitivity (HOMA) was calculated using the following equation: Insulin Resistance (IR) = Blood Glucose  $\times$  [Serum Insulin (mmol/L  $\cdot$  pmol/L)/22.5], as modified from Matthews et al.<sup>22</sup> Serum triglycerides and cholesterol were measured by lipase/glycerol kinase and cholesterol oxidase methods, respectively, on a Cobas Bio fast centrifugal analyzer (Roche Products, Ltd) using a commercial kit (Boehringer Mannheim). Insulin<sup>23</sup> and C-peptide<sup>24</sup> were measured by radioimmunoassay with interassay coefficients of variation of 6.8% and 4.4%, respectively.

### Statistical Analysis

Analyses were performed using the SPSS.<sup>25</sup> Methods included one-way ANOVA, Student's *t* test to compare group mean values, multiple linear regression analysis, and correlations assessed by univariate analysis using Spearman's rank correlation coefficient (*r*). Results are presented as mean  $\pm$  SE.

### Results

The hypertensive and normotensive groups were matched for age, sex, and body mass index (Table 1). Percentage body fat, although higher in the hypertensive group compared with the normotensive group (25.5% versus 18.2%;  $P = .08$ ) did not reach statistical significance. The waist/hip ratios of the two groups were also similar, indicating proportionately similar central fat distribution despite the tendency to a different total body fat content. The mean systolic and diastolic blood pressure measurements were obviously significantly greater in the hypertensive group than the normotensive group.

Blood glucose and serum insulin responses to a 75-g oral glucose load in the two groups are shown in Table 2. All subjects had normal glucose tolerance. The blood glucose responses of the two groups were comparable except for the slightly but significantly higher fasting levels in the hypertensive group ( $P = .04$ ). Basal insulin levels tended to be higher in hypertensive subjects, whereas other values were not significantly different.

Table 3 shows the other metabolic measurements in the two groups. The mean serum total cholesterol levels were significantly elevated in the hypertensive group (4.8 mmol/L versus 3.9 mmol/L);  $P < .05$ , although the triglyceride levels did not differ between the two groups.

The mean MCR was significantly reduced in the hypertensive subjects, whereas the mean SSPI levels achieved during the glucose-insulin infusion were equivalent. The mean SSBG was significantly elevated in the hypertensive

**TABLE 2. Mean Levels of Blood Glucose (mmol/L) and Serum Insulin (mU/L) or (pmol/L) in Response to 75 g Oral Glucose in Hypertensive and Normotensive Subjects**

Time	Hypertensive (n=15)	Normotensive (n=15)
Blood glucose, mmol/L		
Fasting	4.4 (0.1)†	4.1 (0.1)
15 min	5.5 (0.3)	4.9 (0.2)
30 min	6.7 (0.3)	6.7 (0.4)
60 min	6.8 (0.5)	7.3 (0.3)
120 min	4.8 (0.3)	5.4 (0.2)
Serum insulin, mU/L		
Fasting	11.1 (3.3) [67]	5.2 (0.9) [31]
15 min	28.1 (5.4) [169]	21.7 (4.8) [130]
30 min	53.4 (8.4) [320]	43.2 (6.0) [260]
60 min	46.6 (6.7) [280]	68.7 (12.7) [412]
120 min	38.3 (9.2) [230]	59.0 (13.9) [354]

Mean values for insulin given as picomoles per liter in square brackets.  
† $P < .05$ .

group compared with the normotensive subjects. The mean fasting C-peptide levels were similar in both groups, although the mean 150 minutes and 180 minutes levels were significantly higher in the hypertensive group, reflecting the higher glucose levels. The mean fasting serum insulin to fasting blood glucose ratio in the hypertensive group, although higher, did not reach statistical significance. However, basal insulin resistance assessed by the HOMA method was twice as high in hypertensives as in controls (12.84[3.78] versus 5.76[1.08] mmol/L · pmol/L;  $P = .052$ ).

Table 4 shows Spearman's rank correlation coefficients ( $r$ ) of MCR and fasting serum insulin concentration with various variables. There were significant correlations of MCR and fasting insulin only with systolic and diastolic blood pressure. Stepwise multiple linear regression of fasting serum insulin and MCR glucose on systolic and diastolic blood pressure, body mass index, waist/hip ratio, percentage body fat, serum cholesterol, and serum triglyceride was

**TABLE 4. Spearman's Correlation Coefficients of Various Variables with MCR and Fasting Serum Insulin Levels**

Variables	MCR	Fasting Serum Insulin
Systolic blood pressure, mm Hg	-0.53‡	0.53‡
Diastolic blood pressure mm Hg	-0.51‡	0.54‡
Body mass index, kg/m <sup>2</sup>	-0.19	0.33
Waist-hip ratio	-0.34	0.05
Body fat, %	-0.29	0.21
Serum cholesterol, mmol/L	-0.04	0.24
Serum triglycerides, mmol/L	-0.27	0.20

‡ $P < .01$ .

performed. In both the regression models, after diastolic blood pressure ( $r = .52$ ,  $P = .01$ , and  $r = .40$ ,  $P = .04$ ) was entered into the equation, no other variable contributed significantly.

## Discussion

The results of the present study demonstrate that the hypertensive black African subjects show higher SSBG and lower mean MCR of glucose than normotensive subjects, indicating lower insulin sensitivity in the hypertensive group. Previous studies have shown that in the glucose-insulin infusion test,<sup>21</sup> after 150 minutes, steady-state levels of glucose and insulin are achieved. During the steady-state phase, the net glucose and insulin disposal is zero. The mean blood glucose concentration in the steady-state phase therefore reflects the net sensitivity of tissues to insulin stimulated glucose disposal. The MCR of glucose is another index for measuring tissue insulin sensitivity and allows for differences in glucose levels.

The diminished tissue sensitivity to insulin stimulated glucose disposal found in the present study is in keeping with the results obtained in young black American males with borderline hypertension<sup>4</sup> and in black South African male and female subjects with essential hypertension.<sup>18</sup> In the hypertensive group, the metabolic clearance rate of glucose was reduced by 35% compared with that of normotensive subjects.

**TABLE 3. Metabolic Variables During the Glucose-Insulin Infusion Test**

Variables	Hypertensive (n=15)	Normotensive (n=15)
SSBG, mmol/L	5.0 (0.3)‡	3.7 (0.3)
MCR, † $\mu$ mol/kg/min	7.12 (0.57)†	9.50 (0.69)
Fasting serum insulin-blood glucose ratio, I/G	2.6 (0.8)	1.3 (0.2)
SSPI, mU/L (pmol/L)	72.3 (6.1) [434(37)]	70.0 (7.9) [420(47)]
Insulin resistance, HOMA (mmol.pM)	12.84 (3.78)*	5.76 (1.08)
Fasting serum C-peptide, nmol/L	0.20 (0.03)	0.23 (0.03)
150-min serum C-peptide, nmol/L	0.67 (0.12)†	0.31 (0.08)
180-min serum C-peptide, nmol/L	0.59 (0.12)	0.22 (0.09)
Fasting serum cholesterol, nmol/L	4.8 (0.3)	3.9 (0.2)
Fasting serum triglycerides, mmol/L	1.1 (0.2)	0.8 (0.1)

Values for insulin given as picomoles per liter in square brackets.

\* $P = .052$ ; † $P = .05$ ; ‡ $P = .01$ .

Fasting insulin concentration has also been correlated with hypertension,<sup>26,27</sup> although there have been reports of no association<sup>17,28</sup> or weak association<sup>29</sup> in normotensive black African subjects. In the present study, the hypertensive group tended to have higher fasting serum insulin levels compared with normotensive subjects, although the association was not significant. Similarly, the fasting I/G, although higher in the hypertensive subjects than the normotensive subjects, was not statistically significant. However, calculation of basal insulin sensitivity by the HOMA method reached borderline significance. It should be remembered that these measures are of the basal state, whereas the glucose-insulin infusion test, and the euglycemic clamp used by others<sup>1,2</sup> are measurements of the stimulated state so that identical results would not necessarily be expected. Also of interest are the HOMA results in relation to other published values. The control subjects were significantly more insulin sensitive than populations we have studied in the UK and Mauritius.<sup>30,31</sup> This finding is possibly due to the greater physical activity and lower percentage body fat in many populations.

There was a significant positive correlation of fasting levels of serum insulin and a negative correlation of metabolic clearance rate with systolic and diastolic blood pressure independent of waist/hip ratio, body mass index, percent body fat, serum cholesterol, and serum triglycerides. In the present study, where the subjects were non-obese (mean BMI < 25 kg/m<sup>2</sup>), adiposity does not explain the relative insulin resistance, although insulin resistance has been strongly correlated with degree of adiposity.<sup>32</sup> A caveat should be added, however, in that body fat as measured by impedance tended to be higher in hypertensive subjects, although this increase was not significant. Studies in blacks in United States<sup>4</sup> and in South Africa<sup>18</sup> have also reported significant correlation between fasting serum insulin levels and blood pressure levels independent of indices of obesity in nonobese hypertensive subjects, whereas a recent study in urbanized hypertensive Zimbabweans also showed raised fasting insulin levels.<sup>33</sup>

Our study, like other similar studies in black populations in United States<sup>4</sup> and South Africa<sup>18</sup> raises further the possibility of a causal relation between hypertension and insulin resistance. The degree of cause and effect relationship needs further investigation to detect interethnic variations in this and in the full-blown metabolic syndrome.

Few data are available on insulin sensitivity in uncomplicated black hypertension subjects in Africa. The subjects in this study had received no antihypertensive drugs, were normal body weight, and physically active. Similarly they had normal triglyceride levels, although cholesterol levels were slightly higher than in control subjects. Thus the hypertensive subjects lacked the other component parts of the metabolic syndrome. The results show unequivocally that insulin sensitivity was decreased although by a relatively small proportion compared with, for example, the input of diabetes or severe obesity. Thus a black stock, likely to be genetically homogeneous, shows similar features to those found in Europeans.

## Acknowledgment

The financial support of the Overseas Development Association, British Diabetic Association, and North East Diabetes Trust is gratefully acknowledged.

## References

- Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. *N Engl J Med.* 1987;317:350–357.
- Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. *Metabolism.* 1990;39:167–174.
- Sechi LA, Tedde R, Manghano A, Kelis A, Pala A, Orcchioni C. Insulin resistance and B-cell hypersecretion in essential hypertension. *J Hypertens.* 1990;8:S87–S89.
- Flakner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. *Hypertension.* 1990;16:706–711.
- Weidmann P, Bohlen L, deCourten M. Insulin resistance and hyperinsulinaemia in hypertension. *J Hypertens.* 1995;(suppl)13:563–572.
- Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. *N Engl J Med.* 1996;334:374–381.
- Smith U, Gudbjornsdottir S, Landin K. Hypertension as a metabolic disorder: an overview. *J Intern Med.* 1991;229:1–7.
- Bonora E, Zaveroni I, Alghisi O. Relationship between blood pressure and plasma insulin in non-obese and obese non-diabetic subjects. *Diabetologia.* 1987;30:719–723.
- Saad MF, Knowler WC, Pettit DJ, Nelson RG, Mott DM, Bennett PH. Insulin and hypertension: relationship to obesity and glucose intolerance in Pima Indians. *Diabetes.* 1990;39:1430–1435.
- Akintewe TA, Adetuyibi A. Obesity and hypertension in diabetic Nigerians. *Trop Geogr Med.* 1986;38:146–149.
- Corry DB, Tuck ML. Glucose and insulin metabolism in hypertension. *Am J Epidemiol.* 1996;16:223–236.
- Fuh MMT, Sheih SM, Wu DA, Chen YD, Reaven GM. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. *Arch Intern Med.* 1987;147:1035–1038.
- Mallakh RSE. Hypertension and diabetes in obesity: a review and new ideas on the contributing role of ions. *Med Hypotheses.* 1986;19:47–55.
- Reaven G. Role of insulin resistance in human disease. *Diabetes.* 1988;37:1595–1607.
- Dowse GK, Collins VR, Alberti KGMM, Zimmet PZ, Tuomilehto J, Chitson P, Gareeboo H. Insulin and blood pressure levels are not independently related in Mauritians of Asian Indian, Creole or Chinese origin. *J Hypertens.* 1993;11:297–307.
- Asch S, Wingard DL, Varrett-Connor EL. Are insulin and hypertension independently related? *Ann Epidemiol.* 1991;1:23–44.
- Joffe BI, Panz VR, Wing JR, Raal FJ, Sefel HC. Relationships between plasma insulin and blood pressure in South African black women in Johannesburg. *Diabetes Care.* 1992;339:1339–1340.
- Wing JR, Van-Der Merwe MT, Joffe BI, Panz VR, Sefel HC. Insulin mediated glucose disposal in black South Africans with essential hypertension. *Q J Med.* 1994;87:431–436.
- Report of a WHO Study Group. *Diabetes Mellitus.* Geneva, World Health Organization. Technical Report Series 727. 1985;10–12.
- Fulcher GR, Farrer M, Walker M, Rodham D, Clayton B, Alberti KGMM. A comparison of measurements of lean body mass derived by biochemical impedance, skinfold thickness and total body potassium. A study in obese and non-obese normal subjects. *Scan J Clin Lab Invest.* 1991;51:245–253.
- Heine RJ, Home PD, Poncher M, Orskov H, Hammond V, McCulloch AJ, Hanning I, Alberti KGMM. A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. *Diabetes Res Clin Pract.* 1985;2:113–120.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985;28:412–419.

23. Hanning I, Home PD, Alberti KGMM. Measurement of free insulin concentration: the influence of timing of extraction of insulin antibodies. *Diabetologia*. 1985;28:831–835.
24. Heding LG. Radioimmunological determination of human C-peptide in serum. *Diabetologia*. 1975;11:541–545.
25. Statistical Package for Social Sciences PC+4.0, 1990, Chicago: SPSS, Inc.
26. Christlieb AR, Krolewski AS, Warram JH, Soeldner JS. Is insulin the link between hypertension and obesity? *Hypertension*. 1987;7(suppl II):II-54–II-57.
27. Manicardi V, Camellini L, Bellodi G, Coscelli C, Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinaemia in obese man. *J Clin Endocrinol Metab*. 1986;62:1302–1304.
28. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, De Gregorio M, Ravussin E, Knowler WC, Bennett PH, Howard BV. Racial differences in the relation between blood pressure and insulin resistance. *N Engl J Med*. 1991;324:733–739.
29. Folsom AR, Burke GL, Ballew C, Jacobs DR, Haskell WL, Donahue RP, Liu KA, Hilner JE. Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. *Am J Epidemiol*. 1989;130:911–924.
30. Winocour PH, Kaluvya S, Brown L, Farrer M, Millar JP, Neil HAW, Alberti KGMM. The association of different measures of insulinaemia with vascular risk factors in healthy normoglycaemic normotensive non-obese men and women. *Q J Med*. 1991;79:539–560.
31. Dowse GK, Qin H, Collins VR, Zimmet PZ, Alberti KGMM, Gareeboo H for the Mauritius NCD Study Group. Determinants of estimated insulin resistance and B-cell function in Indian, Creole and Chinese Mauritians. *Diabetes Res Clin Pract*. 1990;10:265–279.
32. Olefsky JM, Kolterman OG. Mechanisms of insulin resistance in obesity and non-insulin-dependent (Type II) diabetes. *Am J Med*. 1981;70:151–168.
33. Mufunda J, Sigola LB, Chifamba J, Vengesa PM. Aspects of insulin resistance in urbanisation-related hypertension in Zimbabwe: a preliminary report. *J Hum Hypertens*. 1994;8:481–484.